Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) had its price objective boosted by Piper Sandler from $33.00 to $38.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have an overweight rating on the specialty pharmaceutical company's stock.
Supernus Pharmaceuticals Trading Up 2.2 %
Shares of SUPN opened at $34.23 on Wednesday. The stock's 50 day moving average is $31.35 and its two-hundred day moving average is $30.22. The firm has a market capitalization of $1.83 billion, a PE ratio of 33.89 and a beta of 1.04. Supernus Pharmaceuticals has a twelve month low of $24.95 and a twelve month high of $36.08.
Get
Supernus Pharmaceuticals alerts:
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.15). The business had revenue of $170.10 million during the quarter, compared to analyst estimates of $164.23 million. Supernus Pharmaceuticals had a net margin of 9.12% and a return on equity of 6.98%. The company's revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 earnings per share. On average, sell-side analysts predict that Supernus Pharmaceuticals will post 1.51 EPS for the current year.
Insider Buying and Selling at Supernus Pharmaceuticals
In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 39,431 shares of the firm's stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $31.15, for a total value of $1,228,275.65. Following the sale, the chief executive officer now owns 724,978 shares in the company, valued at $22,583,064.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Tami Tillotson Martin sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $32.98, for a total value of $164,900.00. Following the completion of the transaction, the vice president now owns 87,220 shares of the company's stock, valued at approximately $2,876,515.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jack A. Khattar sold 39,431 shares of the firm's stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $31.15, for a total transaction of $1,228,275.65. Following the completion of the transaction, the chief executive officer now directly owns 724,978 shares of the company's stock, valued at approximately $22,583,064.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,733 shares of company stock worth $2,161,863. 7.99% of the stock is owned by company insiders.
Hedge Funds Weigh In On Supernus Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. ProShare Advisors LLC boosted its stake in shares of Supernus Pharmaceuticals by 4.4% during the 4th quarter. ProShare Advisors LLC now owns 19,862 shares of the specialty pharmaceutical company's stock valued at $578,000 after buying an additional 843 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in Supernus Pharmaceuticals by 4.3% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 97,789 shares of the specialty pharmaceutical company's stock worth $2,852,000 after acquiring an additional 3,997 shares during the period. Bank of America Corp DE raised its holdings in Supernus Pharmaceuticals by 10.9% in the 4th quarter. Bank of America Corp DE now owns 534,919 shares of the specialty pharmaceutical company's stock worth $15,597,000 after acquiring an additional 52,661 shares during the period. Natixis Advisors L.P. raised its holdings in Supernus Pharmaceuticals by 22.5% in the 4th quarter. Natixis Advisors L.P. now owns 26,997 shares of the specialty pharmaceutical company's stock worth $787,000 after acquiring an additional 4,953 shares during the period. Finally, First Republic Investment Management Inc. grew its position in Supernus Pharmaceuticals by 5.9% in the 4th quarter. First Republic Investment Management Inc. now owns 22,595 shares of the specialty pharmaceutical company's stock worth $659,000 after purchasing an additional 1,262 shares during the last quarter. Institutional investors and hedge funds own 99.81% of the company's stock.
Supernus Pharmaceuticals Company Profile
(Get Rating)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
Further Reading
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Is World Wresting Entertainment Getting Ready to Be Sold?
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
